GLOBAL TRENDS AND PROBLEMS OF INFECTIOUS DISEASES – COVID-19, HIV/AIDS, TUBERCULOSIS
Vol. 32 No. 4 (2024), Review articles
Vol. 32 No. 4 (2024)

GLOBAL TRENDS AND PROBLEMS OF INFECTIOUS DISEASES – COVID-19, HIV/AIDS, TUBERCULOSIS

Review articles
https://doi.org/10.35465/32.4.2024.pp55-71
Published May 1, 2025
Jaklin Svetoslavova Doncheva - Dilova
Bulgarian / Italian
V Milanov
Vladimira Boyadzhieva
Nikolay Stoilov
PDF ENG
PDF BG

Keywords

Keywords: global trends, issues, strategies, Covid – 19, HIV / AIDS, tuberculosis

How to Cite

Doncheva - Dilova, J., Milanov, V., Boyadzhieva, V., & Stoilov, N. (2025). GLOBAL TRENDS AND PROBLEMS OF INFECTIOUS DISEASES – COVID-19, HIV/AIDS, TUBERCULOSIS. Rheumatology (Bulgaria), 32(4), 55-71. https://doi.org/10.35465/32.4.2024.pp55-71
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Summary: Globalization and the interconnectedness of countries in the modern world pose new challenges to public health. Over the centuries, infectious diseases have proven to be one of the major threats to global health. Historically, several pandemics and epidemics have changed and claimed the lives of millions of people around the world. Many infectious agents continue to pose a serious problem despite advances in medicine, public health awareness campaigns and vaccination. The aim of this review is to review global epidemiological trends and challenges related to three key infectious diseases: COVID-19, HIV/AIDS, and tuberculosis. The COVID-19 pandemic, along with the long-standing threats of HIV/AIDS and tuberculosis, is posing a serious challenge to health systems and socio-economic structures in many countries. COVID-19, caused by SARS-CoV-2, has spread rapidly around the world, resulting in significant numbers of cases, deaths, and long-term health problems. The consequences of infection “long” COVID-19 and post-COVID-19 unlocked syndromes have become one of the main causes of reduced work capacity and impaired quality of life in recent years. At the same time, HIV/AIDS remains a global health problem, especially in certain regions, and tuberculosis continues to pose a serious threat, especially in conditions of limited access to health services. Each of these health problems poses specific requirements for treatment and prevention, while leading to serious health, social and economic consequences, despite global initiatives and strategies to address them.

https://doi.org/10.35465/32.4.2024.pp55-71
PDF ENG
PDF BG

References

  1. Francesco Robert Burkert, Lukas Lanser, Rosa Bellmann-Weiler and Günter Weiss.
  2. Coronavirus Disease 2019: Clinics, Treatment, and Prevention. Front. Microbiol., 11 November
  3. , Sec. Infectious Agents and Disease, Volume 12 - 2021
  4. https://doi.org/10.3389/fmicb.2021.761887
  5. Manuel Ramos-Casals, Pilar Brito-Zerón, Xavier Mariette. Systemic and organ-specific
  6. immune-related manifestations of COVID-19. Nature REVIEWS. Rheumatology. 2021
  7. Jun;17(6):315-332. doi: 10.1038/s41584-021-00608-z. Epub 2021 Apr 26.
  8. С. Емин, Вл. Бояджиева, Н. Стоилов, Ж. Димова, М. Иванова, Р. Стоилов.
  9. Автоимунни заболявания, отключени след ваксинация срещу COVID-19. MedInfo
  10. ;5:18-21.
  11. Dimova, Z., Boyadzhieva, V., Stoilov, N., Monov, S., & Stoilov, R. (2021). COVID-19
  12. IN AUTOIMMUNE RHEUMATIC DISEASES - FREQUENCY, COURSE, EFFECTIVENESS
  13. AND COMPLICATIONS IN VACCINATION. Rheumatology (Bulgaria), 29(4), 87-98.
  14. https://doi.org/10.35465/29.4.2021.pp87-98
  15. Stoilov, N., & Boyadzhieva, V. (2021). SARS-CoV-2 and autoimmune rheumatic
  16. diseases. Rheumatology (Bulgaria), 28(4), 36-44. https://doi.org/10.35465/28.4.2020.pp36-44
  17. Dimova, Z., Boyadzhieva, V., Stoilov, N., Emin, S., Nikolov, N., & Stoilov, R. (2022). A
  18. clinical case of a patient with mucocutaneous and musculoskeletal manifestations after COVID-
  19. vaccination. Rheumatology (Bulgaria), 30(2), 102-107.
  20. https://doi.org/10.35465/30.2.2022.pp102-107
  21. Rachana Vanaparthy, Srikrishna V. Malayala, Mamtha Balla. COVID-19-Induced
  22. Vestibular Neuritis, Hemi-Facial Spasms and Raynaud's Phenomenon: A Case Report. Cureus.
  23. Nov; 12(11): e11752. doi: 10.7759/cureus.11752
  24. Alberto Sulli, Emanuele Gotelli, Pietro Francesco Bica, Irene Schiavetti, Carmen
  25. Pizzorni, Teresita Alo`e, Marco Grosso, Emanuela Barisione, Sabrina Paolino, Vanessa Smith,
  26. Maurizio Cutolo. Detailed videocapillaroscopic microvascular changes detectable in adult
  27. COVID-19 survivors.
  28. Figen Çakmak, Asuman Demirbuga , Demet Demirkol , Süheyla Gümüş , Selda Hancerli
  29. Torun , Gülşah Kavrul Kayaalp , Rukiye Eker Ömeroglu , Ayper Somer , Metin Uysalol , Raif
  30. Yıldız , Nuray Aktay Ayaz. Nailfold capillaroscopy: A sensitive method for evaluating
  31. microvascular involvement in children with SARS-CoV-2 infection. Microvascular Research.
  32. Volume 138, November 2021, 104196. DOI: 10.1016/j.mvr.2021.104196
  33. Gerlando Natalello , Giacomo De Luca , Laura Gigante , Corrado Campochiaro , Enrico
  34. De Lorenzis , Lucrezia Verardi , Annamaria Paglionico , Luca Petricca , Anna Maria Martone ,
  35. Stefania Calvisi , Marco Ripa , Giulio Cavalli , Emanuel Della-Torre , Moreno Tresoldi ,
  36. Francesco Landi , Silvia Laura Bosello , Elisa Gremese , Lorenzo Dagna. Nailfold
  37. capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of
  38. COVID-19 microvascular involvement. Microvascular Research 2021 Jan;133:104071. doi:
  39. 1016/j.mvr.2020.104071.
  40. Doncheva - Dilova, J., Boyadzhieva, V., & Stoilov, N. (2023). Clinical and immune-
  41. related manifestations in patients with COVID-19. Rheumatology (Bulgaria), 31(1), 54-94.
  42. https://doi.org/10.35465/31.1.2023.pp54-94
  43. Joshee S, Vatti N, Chang C. Long-Term Effects of COVID-19. Mayo Clin Proc
  44. ;97:57999. https://doi.org/10.1016/j.mayocp.2021.12.017
  45. WHO. COVID-19 epidemiological update – 24 December 2024. Available at:
  46. https://cdn.who.int/media/docs/default-source/documents/emergencies/20241224_covid-
  47. _epi_update_special-edition.pdf?sfvrsn=b0a6ddaf_1&download=true
  48. Limb M. Covid-19: Recognise long covid as occupational disease and compensate
  49. frontline workers, say MPs BMJ 2021; 372 :n503 doi:10.1136/bmj.n503
  50. https://www.bmj.com/content/372/bmj.n503
  51. Himmelstein DU, Woolhandler S. Health insurance status and risk factors for poor
  52. outcomes with COVID-19 among U.S. health care workers: a cross-sectional study. Ann Intern
  53. Med. 2020; 173: 410-412. https://doi.org/10.7326/m20-1874
  54. McMahon DE, Peters GA, Ivers LC, Freeman EE. Global resource shortages during
  55. COVID-19: Bad news for low-income countries. PLoS Negl Trop Dis. 2020; 14(7):e0008412.
  56. https://doi.org/10.1371/journal.pntd.0008412
  57. Covid-19: An Occupational Disease, TUC, August 2022
  58. Workers’ experiences of long Covid, A joint report by the TUC and Long Covid Support,
  59. March 2023. https://www.tuc.org.uk/sites/default/files/2023-
  60. /Long%20Covid%20at%20Work%20report%20-%20FINAL%20COLOUR%202.pdf
  61. Robinson-Lane SG, Sutton NR, Chubb H, Yeow RY, Mazzara N, DeMarco K, Kim T,
  62. Chopra V. Race, Ethnicity, and 60-Day Outcomes After Hospitalization With COVID-19. J Am
  63. Med Dir Assoc. 2021 Nov;22(11):2245-2250. doi: 10.1016/j.jamda.2021.08.023. Epub 2021 Oct
  64. PMID: 34716006; PMCID: PMC8490827.
  65. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes
  66. Among Patients Hospitalized With COVID-19. Ann Intern Med. 2021 Apr;174(4):576-578. doi:
  67. 7326/M20-5661. Epub 2020 Nov 11. PMID: 33175566; PMCID: PMC7707210.
  68. Richards F, Kodjamanova P, Chen X, Li N, Atanasov P, Bennetts L, Patterson BJ,
  69. Yektashenas B, Mesa-Frias M, Tronczynski K, Buyukkaramikli N, El Khoury AC. Economic
  70. Burden of COVID-19: A Systematic Review. Clinicoecon Outcomes Res. 2022 Apr 28;14:293-
  71. doi: 10.2147/CEOR.S338225. PMID: 35509962; PMCID: PMC9060810.
  72. Doncheva - Dilova, J., Boyadzhieva, V., & Kuneva, T. (2024). COVID-19 and post-
  73. COVID-19 syndrome as an occupational disease. Rheumatology (Bulgaria), 31(4), 60-77.
  74. https://doi.org/10.35465/31.4.2023.pp60-77
  75. Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global
  76. Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of
  77. Pandemic Measures and Problems. J Pers Med. 2022 Aug 7;12(8):1295. doi:
  78. 3390/jpm12081295. PMID: 36013244; PMCID: PMC9409667.
  79. Naeem FN, Hasan SFS, Ram MD, Waseem S, Ahmed SH, Shaikh TG. The association
  80. between SARS-CoV-2 vaccines and transverse myelitis: A review. Ann Med Surg (Lond). 2022
  81. Jun 9;79:103870. doi: 10.1016/j.amsu.2022.103870. PMID: 35702684; PMCID: PMC9181565.
  82. Cherif, Y.Y.S.; Djeffal, C.; Abu Serhan, H.; Elnahhas, A.; Yousef, H.; Katamesh, B.E.;
  83. Abdelazeem, B.; Abdelaal, A. The Characteristics of COVID-19 Vaccine-Associated Uveitis: A
  84. Summative Systematic Review. Vaccines 2023, 11, 69.
  85. https://doi.org/10.3390/vaccines11010069
  86. Carlsten C, Gulati M, Hines S, Rose C, Scott K, Tarlo SM, Torén K, Sood A, de la Hoz RE.
  87. COVID-19 as an occupational disease. Am J Ind Med. 2021 Apr;64(4):227-237. doi:
  88. 1002/ajim.23222. Epub 2021 Jan 24. PMID: 33491195; PMCID: PMC8014565.
  89. Burdorf A, Porru F, Rugulies R. The COVID-19 (Coronavirus) pandemic: consequences
  90. for occupational health. Scand J Work Environ Health. 2020 May 1;46(3):229-230. doi:
  91. 5271/sjweh.3893. PMID: 32356896.
  92. WHO. COVAX. Working for global equitable access to COVID-19 vaccines. Available from:
  93. https://www.who.int/initiatives/act-accelerator/covax
  94. Димитров И., Владимиров К., Мерки за рестарт на туризма и успешното провеждане
  95. на сезон 2021 в условията на COVID-19 - Сборник доклади от Черноморски туристически
  96. форум, с. 131-142, ISBN 978-954-9741-45-2 – 2021
  97. European Commission. (2020, July 21). EU leaders agree on €1.8 trillion budget and
  98. recovery plan. European Commission. Available at:
  99. https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2073
  100. The White House. (2021, March 11). The American Rescue Plan Act of 2021: A
  101. comprehensive economic relief package. The White House. Available at:
  102. https://www.whitehouse.gov/american-rescue-plan
  103. Federal Transit Administration. American Rescue Plan Act of 2021. Available from:
  104. https://www.transit.dot.gov/funding/american-rescue-plan-act-2021
  105. U.S. Department of Labor. Delivering immediate relief to America's workers. Available
  106. from: https://www.dol.gov/general/american-rescue-plan
  107. World Health Organization (WHO). (2021). COVID-19 vaccination and social distancing:
  108. Global challenges and successes. World Health Organization. https://www.who.int/news-
  109. room/fact-sheets/detail/coronavirus-disease-(covid-19)
  110. Gössling, S., Scott, D., & Hall, C. M. (2020). Pandemics, tourism and global change: A rapid
  111. assessment of COVID-19. Journal of Sustainable Tourism, 29(1), 1-19.
  112. Fuchs F, Morf H, Mohn J et al. Diagnostic delay stages and pre-diagnostic treatment in
  113. patients with suspected rheumatic diseases before special care consultation: results of a
  114. multicenter-based study. Rheumatol Int 2023, 43, 495-502. https://doi.org/10.1007/s00296-022-
  115. -
  116. Fuchs et al; Dimitrov, I. (2024). Medical and SPA tourism and rheumatic diseases –
  117. challenges and future perspective. Rheumatology (Bulgaria), 32(1), 30-44.
  118. https://doi.org/10.35465/32.1.2024.pp30-44
  119. Dimitrov, I. (2024). Medical and SPA tourism and rheumatic diseases – challenges and future
  120. perspective. Rheumatology (Bulgaria), 32(1), 30-44. https://doi.org/10.35465/32.1.2024.pp30-44
  121. Widdifield J, Bernatsky S, Thorne JC, Bombardier C, Jaakkimainen RL, Wing L, Paterson
  122. JM, Ivers N, Butt D, Lyddiatt A, Hofstetter C, Ahluwalia V, Tu K. Wait times to rheumatology
  123. care for patients with rheumatic diseases: a data linkage study of primary care electronic medical
  124. records and administrative data. CMAJ Open. 2016 May 11;4(2):E205-12. doi:
  125. 9778/cmajo.20150116.
  126. United Nations Programme on HIV/AIDS (UNAIDS). Global HIV & AIDS Statistics.
  127. UNAIDS. Available at: https://www.unaids.org
  128. World Health Organization (WHO). Global Health Reports. World Health Organization.
  129. Available at: https://www.who.int
  130. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted
  131. infections for the period 2022-2030. Available at:
  132. https://iris.who.int/bitstream/handle/10665/360348/9789240053779-eng.pdf?sequence=1
  133. Checkpoint. Център за сексуално здраве София. PrEP. Налично на:
  134. https://checkpointsofia.info/useful/prep/
  135. U.S. Department of State. The Global Fund to Fight AIDS, Tuberculosis, and Malaria. U.S.
  136. Government Positions on Decision Points from the Forty-sixth Board Meeting of the Global
  137. Fund. Available at: https://www.state.gov/wp-content/uploads/2021/12/Outcomes-of-the-GF-
  138. th-Board-Meeting-Final.pdf
  139. Община Варна. „Дирекция Превенции“. Лечение при ХИВ и СПИН. Налично на:
  140. https://prevencii.com/index.php/pol-inf/%D1%85%D0%B8%D0%B2-
  141. %D1%81%D0%BF%D0%B8%D0%BD/30-%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5-
  142. %D0%BF%D1%80%D0%B8-%D1%85%D0%B8%D0%B2-%D0%B8-%D1%81%D0%BF%D0%B8%D0%BD
  143. Clinica.bg. Днес е достатъчна 1 таблетка срещу ХИВ. Налично на:
  144. https://clinica.bg/22822-dnes-e-dostatychna-1-tabletka-sreshtu-hiv
  145. World Health Organization (WHO). Global Tuberculosis Report 2024. World Health
  146. Organization. Available at: https://iris.who.int/bitstream/handle/10665/379339/9789240101531-
  147. eng.pdf?sequence=1
  148. Ж. Дончева-Дилова, В. Миланов. Силикотуберкулоза – съвременни аспекти,
  149. предизвикателства и подходи. Обща медицина, 2023, 25(6), 44-52
  150. Sharma N, Kundu D, Dhaked S et al. Silicosis and silicotuberculosis in India. Bull World
  151. Health Organ, 2016;94(10):777-778. doi: 10.2471/BLT.15.163550.
  152. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet, 2016;387(10024):1211-26. doi:
  153. 1016/S0140-6736(15)00151-8
  154. Corbett EL, Churchyard GJ, Clayton T et al. Risk factors for pulmonary mycobacterial
  155. disease in South African gold miners. A case-control study. Am J Respir Crit Care Med,
  156. ;159(1):94-9. doi: 10.1164/ajrccm.159.1.9803048.
  157. Stop TB Partnership. Available at: https://www.stoptb.org
  158. International Labour Organization. Biological hazards in the working environment. Geneva:
  159. International Labour Office, 2022. ISBN 978-92-2-038343-8 (web PDF). Налично на:
  160. https://www.ilo.org/resource/conference-paper/biological-hazards-working-environment.
  161. Corrao CR, Mazzotta A, La Torre G, et al. Biological risk and occupational health. Ind
  162. Health. 2012;50(4):326-37. doi: 10.2486/indhealth.ms1324. Epub 2012 Jun 13. PMID:
  164. Eurofound (2017), Sixth European Working Conditions Survey – Overview report (2017
  165. update), Publications Office of the European Union, Luxembourg. European Foundation for the
  166. Improvement of Living and Working Conditions, 2017. ISBN 978-92-897-1597-3; doi:
  167. 2806/422172; TJ-02-17-731-EN-N. Налично на:
  168. https://www.eurofound.europa.eu/en/publications/2016/sixth-european-working-conditions-
  169. survey-overview-report.
  170. Takala J, Descatha A, Oppliger A, et al. Global Estimates on Biological Risks at Work. Saf
  171. Health Work. 2023 Dec;14(4):390-397. doi: 10.1016/j.shaw.2023.10.005. Epub 2023 Oct 5.
  172. PMID: 38187195; PMCID: PMC10770103.
  173. UNI Global Union и ITUC. COVID-19: AN OCCUPATIONAL DISEASE WHERE
  174. FRONTLINE WORKERS ARE BEST PROTECTED. 18.05.21
  175. https://uniglobalunion.org/report/covid-19-an-occupational-disease-where-frontline-workers-are-
  176. best-protected/?fbclid=IwAR2yuptL4sNJNgy6pAezs1h30xFoOU8cR5lfKwqPZSJcw7fpSQwhsVgtuRQ
  177. Sandal A, Yildiz AN. COVID-19 as a Recognized Work-Related Disease: The Current
  178. Situation Worldwide. Saf Health Work. 2021 Mar;12(1):136-138. doi:
  179. 1016/j.shaw.2021.01.001. Epub 2021 Jan 22. PMID: 33520326; PMCID: PMC7826036.
  180. Национална здравна стратегия 2020. Налична на:
  181. https://old.parliament.bg/pub/plenary_documents/502-03-
  182. _Natsionalna%20zdravna%20strategiya%202020.pdf.
  183. Национален център по обществено здраве и анализи. Годишен доклад за състоянието
  184. на здравето на гражданите в Република България за 2022 г. София, 2022. Налично на:
  185. https://ncpha.government.bg/index/103-dokladi-i-analizi.html.
  186. Министерство на здравеопазването на Република България. Налично на:
  187. https://www.mh.government.bg/
  188. Национален център по заразни и паразитни болести. Налично на:
  189. https://www.ncipd.org/index.php?lang=bg
  190. United Nations. Sustainable Development Goals. Available at: https://sdgs.un.org/goals
  191. НАЦИОНАЛНА ПРОГРАМА ЗА ПРЕВЕНЦИЯ И КОНТРОЛ НА ХИВ И
  192. СЕКСУАЛНО ПРЕДАВАНИ ИНФЕКЦИИ В РЕПУБЛИКА БЪЛГАРИЯ 2021 - 2025 г.
  193. Налично на:
  194. file:///C:/Users/User1/Downloads/%D0%9D%D0%B0%D1%86%D0%B8%D0%BE%D0%BD
  195. %D0%B0%D0%BB%D0%BD%D0%B0%20%D0%BF%D1%80%D0%BE%D0%B3%D1%80
  196. %D0%B0%D0%BC%D0%B0%20%D0%B7%D0%B0%20%D0%BF%D1%80%D0%B5%D0
  197. %B2%D0%B5%D0%BD%D1%86%D0%B8%D1%8F%20%D0%B8%20%D0%BA%D0%BE
  198. %D0%BD%D1%82%D1%80%D0%BE%D0%BB%20%D0%BD%D0%B0%20%D0%A5%D0
  199. %98%D0%92%20%D0%B8%20%D1%81%D0%B5%D0%BA%D1%81%D1%83%D0%B0%
  200. D0%BB%D0%BD%D0%BE%20%D0%BF%D1%80%D0%B5%D0%B4%D0%B0%D0%B2%
  201. D0%B0%D0%BD%D0%B8%20%D0%B8%D0%BD%D1%84%D0%B5%D0%BA%D1%86%
  202. D0%B8%D0%B8%20%D0%B2%20%D0%A0%D0%91%20%D0%B7%D0%B0%20%D0%BF
  203. %D0%B5%D1%80%D0%B8%D0%BE%D0%B4%D0%B0%202021-2025%20%D0%B3.pdf
  204. Министерски съвет. Национална програма за превенция и контрол на ХИВ и сексуално
  205. предавани инфекции в Ре­публика България за периода 2021 - 2025 г. Налично на:
  206. https://www.mh.government.bg/media/filer_public/2021/08/13/21rh594pr1.pdf
  207. Министерство на здравеопазването. Национален център по обществено здраве и
  208. анализи. Здравеопазване. Кратък статистически справочник. Налично на:
  209. https://ncpha.government.bg./uploads/magazines/healthcare/Healthcare_24.pdf
  210. Национален осигурителен институт. Статистическа система „Професионални
  211. болести". Признати професионални болести. 2009-2022 г. Налично на:
  212. https://www.nssi.bg/publikacii/statistika/trudovi-zlopoluki/informatsiya-za-profesionalni-
  213. bolesti/.
  214. Вангелова К. Превенция на професионалните и свързани с труда заболявания.
  215. Списание „Здраве и безопасност при работа“. Национален център по обществено здраве и
  216. анализи. 2022, 8
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

Most read articles by the same author(s)

1 2 3 4 > >>